Retatrutide · 60 mg
Published- batch · LOT
- B-2026-RETA-60-002
- Laboratory
- Testides
- purity
- 99.94%
- Test date
- 16.07.2026
Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
Retatrutide — a research peptide and triple GIP/GLP-1/glucagon receptor agonist. Lyophilized, every batch HPLC-tested.
Selected size: 5 mg
60 mg analysis published
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (weeks 1–4) | 2.5 mg once weekly subcutaneously | Starting dose |
| Titration (every 4 weeks) | 5 → 10 mg once weekly | Increase if needed |
| Upper bound of this schedule | 15 mg once weekly | Maximum in this schedule |
FAQ
Find answers to questions about Retatrutide and related materials.
The half-life of retatrutide is approximately 6 days by subcutaneous administration, from the phase 1b study (Lancet). Retatrutide is investigational — no approved FDA/EMA label exists, so the half-life is known from clinical publications rather than a regulatory document. See the Dosing section for detail.
Source / documentationCertificates shown: 1
Share your experience
No reviews yet. Tell others what you think of this product.
Retatrutide is an investigational molecule that activates GIP, GLP-1 and glucagon receptors at the same time. It is supplied as a lyophilized powder for laboratory research (RUO). According to the phase 1b study, its half-life after subcutaneous administration is about 6 days.
The mechanism, structure and sources are described in the retatrutide monograph. Clinical studies are reviewed in the study results overview.
Find the LOT number on the vial label and match it with the report. Reports for each batch are kept in the COA archive. A report confirms analytics at the time of testing, not the medical status of the material.
Retatrutide activates three receptors, while most comparable compounds act on only one or two. For comparison, see semaglutide, tirzepatide and liraglutide.
Supplied form: lyophilized powder. Storage, dissolution and laboratory handling are described in the batch documentation.
| Topic | Material |
|---|---|
| Mechanism and research | retatrutide monograph |
| Clinical results | study results overview |
| Form, dissolution, storage | batch documentation |
| Batch verification, COA | COA archive |
Reference material. Not medical advice. The sample is for laboratory research only (RUO). Mounjaro, Zepbound and other named brands are trademarks of their owners.
Buy 2, get the 3rd free
The set contains two vials of 60 mg.
120 mg: Best value · Save ≈ $57.73
